<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p145" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_145{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_145{left:306px;bottom:30px;}
#t3_145{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_145{left:346px;bottom:30px;}
#t5_145{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_145{left:517px;bottom:30px;}
#t7_145{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_145{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_145{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_145{left:1124px;bottom:27px;letter-spacing:0.2px;}
#tb_145{left:35px;bottom:777px;letter-spacing:0.09px;word-spacing:0.09px;}
#tc_145{left:35px;bottom:754px;letter-spacing:0.03px;word-spacing:0.15px;}
#td_145{left:35px;bottom:731px;letter-spacing:0.13px;word-spacing:0.06px;}
#te_145{left:35px;bottom:707px;letter-spacing:0.08px;word-spacing:0.1px;}
#tf_145{left:35px;bottom:684px;letter-spacing:0.15px;word-spacing:-0.14px;}
#tg_145{left:35px;bottom:661px;letter-spacing:0.17px;word-spacing:0.02px;}
#th_145{left:35px;bottom:638px;letter-spacing:0.13px;word-spacing:0.06px;}
#ti_145{left:35px;bottom:614px;letter-spacing:0.13px;word-spacing:0.06px;}
#tj_145{left:35px;bottom:591px;letter-spacing:0.19px;}
#tk_145{left:277px;bottom:599px;}
#tl_145{left:295px;bottom:591px;letter-spacing:0.12px;word-spacing:0.06px;}
#tm_145{left:35px;bottom:568px;letter-spacing:0.08px;word-spacing:-1.12px;}
#tn_145{left:35px;bottom:545px;letter-spacing:0.03px;word-spacing:-0.77px;}
#to_145{left:446px;bottom:552px;letter-spacing:-0.16px;}
#tp_145{left:477px;bottom:545px;letter-spacing:0.07px;word-spacing:-1.12px;}
#tq_145{left:35px;bottom:522px;letter-spacing:0.08px;word-spacing:0.11px;}
#tr_145{left:35px;bottom:498px;letter-spacing:0.04px;word-spacing:0.15px;}
#ts_145{left:35px;bottom:475px;letter-spacing:0.1px;word-spacing:0.09px;}
#tt_145{left:512px;bottom:483px;}
#tu_145{left:35px;bottom:436px;letter-spacing:0.07px;word-spacing:-0.5px;}
#tv_145{left:35px;bottom:413px;letter-spacing:0.1px;word-spacing:0.09px;}
#tw_145{left:496px;bottom:420px;}
#tx_145{left:529px;bottom:413px;letter-spacing:0.44px;}
#ty_145{left:35px;bottom:390px;letter-spacing:0.06px;word-spacing:0.13px;}
#tz_145{left:35px;bottom:366px;letter-spacing:0.26px;word-spacing:-0.07px;}
#t10_145{left:291px;bottom:366px;}
#t11_145{left:306px;bottom:366px;letter-spacing:0.06px;word-spacing:0.13px;}
#t12_145{left:35px;bottom:343px;letter-spacing:0.08px;word-spacing:0.11px;}
#t13_145{left:538px;bottom:351px;}
#t14_145{left:555px;bottom:343px;letter-spacing:-0.37px;}
#t15_145{left:35px;bottom:320px;letter-spacing:0.04px;word-spacing:-0.47px;}
#t16_145{left:35px;bottom:297px;letter-spacing:0.15px;word-spacing:0.04px;}
#t17_145{left:35px;bottom:273px;letter-spacing:0.19px;}
#t18_145{left:35px;bottom:250px;letter-spacing:0.1px;word-spacing:0.09px;}
#t19_145{left:496px;bottom:258px;}
#t1a_145{left:513px;bottom:250px;}
#t1b_145{left:35px;bottom:227px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1c_145{left:35px;bottom:204px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1d_145{left:35px;bottom:181px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1e_145{left:260px;bottom:188px;}
#t1f_145{left:277px;bottom:181px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1g_145{left:35px;bottom:157px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1h_145{left:35px;bottom:134px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1i_145{left:35px;bottom:111px;letter-spacing:0.08px;word-spacing:-1.13px;}
#t1j_145{left:314px;bottom:118px;}
#t1k_145{left:346px;bottom:111px;letter-spacing:0.05px;word-spacing:-0.79px;}
#t1l_145{left:35px;bottom:88px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1m_145{left:35px;bottom:64px;letter-spacing:0.26px;word-spacing:-0.08px;}
#t1n_145{left:618px;bottom:777px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1o_145{left:618px;bottom:754px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1p_145{left:1008px;bottom:754px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1q_145{left:618px;bottom:731px;letter-spacing:0.31px;}
#t1r_145{left:715px;bottom:731px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1s_145{left:618px;bottom:707px;letter-spacing:-0.33px;word-spacing:1.72px;}
#t1t_145{left:708px;bottom:707px;letter-spacing:0.06px;}
#t1u_145{left:829px;bottom:707px;letter-spacing:0.43px;}
#t1v_145{left:618px;bottom:665px;letter-spacing:-0.21px;word-spacing:3.08px;}
#t1w_145{left:618px;bottom:636px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1x_145{left:618px;bottom:614px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1y_145{left:618px;bottom:591px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1z_145{left:618px;bottom:568px;letter-spacing:0.1px;word-spacing:0.09px;}
#t20_145{left:618px;bottom:545px;letter-spacing:0.06px;word-spacing:-0.28px;}
#t21_145{left:618px;bottom:522px;letter-spacing:0.11px;word-spacing:0.08px;}
#t22_145{left:618px;bottom:498px;letter-spacing:0.06px;word-spacing:-1.1px;}
#t23_145{left:618px;bottom:475px;letter-spacing:0.05px;word-spacing:0.14px;}
#t24_145{left:618px;bottom:452px;letter-spacing:0.1px;word-spacing:0.09px;}
#t25_145{left:618px;bottom:429px;letter-spacing:0.07px;word-spacing:-0.87px;}
#t26_145{left:618px;bottom:405px;letter-spacing:0.02px;word-spacing:0.17px;}
#t27_145{left:618px;bottom:382px;letter-spacing:0.1px;word-spacing:-1.14px;}
#t28_145{left:618px;bottom:359px;letter-spacing:0.04px;word-spacing:0.15px;}
#t29_145{left:618px;bottom:336px;letter-spacing:0.15px;word-spacing:0.03px;}
#t2a_145{left:618px;bottom:313px;letter-spacing:0.16px;word-spacing:0.02px;}
#t2b_145{left:618px;bottom:289px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2c_145{left:618px;bottom:266px;word-spacing:0.18px;}
#t2d_145{left:618px;bottom:243px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2e_145{left:618px;bottom:220px;word-spacing:0.19px;}
#t2f_145{left:618px;bottom:179px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2g_145{left:618px;bottom:156px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2h_145{left:618px;bottom:133px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2i_145{left:618px;bottom:110px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2j_145{left:618px;bottom:86px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2k_145{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_145{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_145{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_145{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_145{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_145{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_145{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_145{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_145{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s8_145{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_145{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts145" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg145Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg145" style="-webkit-user-select: none;"><object width="1210" height="935" data="145/145.svg" type="image/svg+xml" id="pdf145" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_145" class="t s0_145">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_145" class="t s1_145">© </span>
<span id="t3_145" class="t s0_145">(NCCN </span>
<span id="t4_145" class="t s1_145">© </span>
<span id="t5_145" class="t s0_145">), All rights reserved. NCCN Guidelines </span>
<span id="t6_145" class="t s1_145">® </span>
<span id="t7_145" class="t s0_145">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_145" class="t s2_145">NCCN Guidelines Version 4.2024 </span>
<span id="t9_145" class="t s2_145">Head and Neck Cancers </span>
<span id="ta_145" class="t s3_145">MS-4 </span>
<span id="tb_145" class="t s4_145">Distinguishing patients with p16 positivity by HPV tumor status informs </span>
<span id="tc_145" class="t s4_145">prognosis. A multicenter individual patient data analysis including 13 </span>
<span id="td_145" class="t s4_145">cohorts of patients from Canada and Europe (N = 7654) showed that </span>
<span id="te_145" class="t s4_145">patients with discordant p16 expression and HPV status (5-year OS of </span>
<span id="tf_145" class="t s4_145">53.2%, 95% CI, 46.6%–60.8% for p16-negative/HPV-positive; 5-year OS </span>
<span id="tg_145" class="t s4_145">of 54.7%, 95% CI, 49.2%–60.9% for p16-positive/HPV-negative) had </span>
<span id="th_145" class="t s4_145">worse prognosis compared to patients with concordant positive p16 </span>
<span id="ti_145" class="t s4_145">expression and HPV status (5-year OS of 81.1%, 95% CI, 79.5%–82.7% </span>
<span id="tj_145" class="t s4_145">for p16-negative/HPV-positive). </span>
<span id="tk_145" class="t s5_145">40 </span>
<span id="tl_145" class="t s4_145">Prognosis was worst for patients with </span>
<span id="tm_145" class="t s4_145">concordant negative p16 expression and HPV status (5-year OS of 40.4%, </span>
<span id="tn_145" class="t s4_145">95% CI, 38.6%–42.4% for p16-negative/HPV-positive). </span>
<span id="to_145" class="t s5_145">41,42 </span>
<span id="tp_145" class="t s4_145">A retrospective </span>
<span id="tq_145" class="t s4_145">cohort analysis (N = 1070) also showed better OS in patients with HPV </span>
<span id="tr_145" class="t s4_145">16/18 positive sinonasal cancer, compared to patients with HPV negative </span>
<span id="ts_145" class="t s4_145">disease (adjusted hazard ratio [HR], 0.63; 95% CI, 0.48–0.82). </span>
<span id="tt_145" class="t s5_145">43 </span>
<span id="tu_145" class="t s4_145">The impact of smoking and cancer stage on survival of patients with HPV- </span>
<span id="tv_145" class="t s4_145">positive SCCHN has been investigated in numerous studies. </span>
<span id="tw_145" class="t s5_145">44-46 </span>
<span id="tx_145" class="t s4_145">For </span>
<span id="ty_145" class="t s4_145">example, analyses of patients with oropharyngeal cancer who were </span>
<span id="tz_145" class="t s4_145">enrolled in RTOG 9003 or 0129 (</span><span id="t10_145" class="t s6_145">n </span><span id="t11_145" class="t s4_145">= 165) showed that smoking was </span>
<span id="t12_145" class="t s4_145">associated with decreased OS and PFS, regardless of p16 status. </span>
<span id="t13_145" class="t s5_145">44 </span>
<span id="t14_145" class="t s4_145">An </span>
<span id="t15_145" class="t s4_145">analysis of data compiled from four cooperative group trials estimated that </span>
<span id="t16_145" class="t s4_145">those who never smoked had a 51% (HR, 0.40; 95% CI, 0.33–0.75) </span>
<span id="t17_145" class="t s4_145">reduction in risk of cancer progression when compared to those who </span>
<span id="t18_145" class="t s4_145">formerly or currently smoked and had HPV-positive SCCHN. </span>
<span id="t19_145" class="t s5_145">46 </span>
<span id="t1a_145" class="t s4_145">A </span>
<span id="t1b_145" class="t s4_145">retrospective analysis from a clinical trial (RTOG 0129) showed no </span>
<span id="t1c_145" class="t s4_145">difference in the rate of distant metastasis in patients with p16-positive </span>
<span id="t1d_145" class="t s4_145">versus p16-negative disease. </span>
<span id="t1e_145" class="t s5_145">32 </span>
<span id="t1f_145" class="t s4_145">Additional analyses have suggested that </span>
<span id="t1g_145" class="t s4_145">individuals with T4 or N3 disease or radiographically detectable matted </span>
<span id="t1h_145" class="t s4_145">lymph nodes may have a worse prognosis, and therefore should be </span>
<span id="t1i_145" class="t s4_145">excluded from deintensification trials. </span>
<span id="t1j_145" class="t s5_145">47-50 </span>
<span id="t1k_145" class="t s4_145">These studies on prognostic and </span>
<span id="t1l_145" class="t s4_145">predictive factors in HPV-positive oropharyngeal cancers form the basis </span>
<span id="t1m_145" class="t s4_145">for RT deintensification studies. Moreover, the striking difference in </span>
<span id="t1n_145" class="t s4_145">prognosis for HPV-positive versus HPV-negative SCCHN led to the </span>
<span id="t1o_145" class="t s4_145">creation of new AJCC staging criteria in 2018 (see </span><span id="t1p_145" class="t s6_145">Cancer of the </span>
<span id="t1q_145" class="t s6_145">Oropharynx </span><span id="t1r_145" class="t s4_145">in the NCCN Guidelines for Head and Neck Cancers; </span>
<span id="t1s_145" class="t s4_145">available at </span><span id="t1t_145" class="t s7_145">www.NCCN.org</span><span id="t1u_145" class="t s4_145">). </span>
<span id="t1v_145" class="t s8_145">Management Approaches </span>
<span id="t1w_145" class="t s4_145">The specific site of disease, histology, stage, and baseline comorbid </span>
<span id="t1x_145" class="t s4_145">conditions guide treatment decisions (eg, the appropriate surgical </span>
<span id="t1y_145" class="t s4_145">procedures, radiotherapy treatment parameters [target volumes, total </span>
<span id="t1z_145" class="t s4_145">dose, and fractionation regimen], indications for systemic therapy, and </span>
<span id="t20_145" class="t s4_145">patient-specific considerations). Single-modality treatment with surgery or </span>
<span id="t21_145" class="t s4_145">RT is generally recommended for the approximately 30% to 40% of </span>
<span id="t22_145" class="t s4_145">patients who present with early-stage disease (stage I or II) HPV-unrelated </span>
<span id="t23_145" class="t s4_145">cancers. Surgery and RT result in similar survival for many H&amp;N cancers, </span>
<span id="t24_145" class="t s4_145">but surgery is usually preferred for oral cavity and paranasal sinus </span>
<span id="t25_145" class="t s4_145">cancers, while RT with or without chemotherapy is nearly always preferred </span>
<span id="t26_145" class="t s4_145">for all stages of nasopharyngeal carcinoma (NPC) and more advanced </span>
<span id="t27_145" class="t s4_145">stages of HPV-associated oropharyngeal cancer. The choice of surgery or </span>
<span id="t28_145" class="t s4_145">RT as the primary treatment modality is often based on local institutional </span>
<span id="t29_145" class="t s4_145">expertise and/or perceived relative morbidity of these treatment options. </span>
<span id="t2a_145" class="t s4_145">With the evolution of conformal techniques of RT and less invasive </span>
<span id="t2b_145" class="t s4_145">surgery, as well as improving supportive care for patients receiving </span>
<span id="t2c_145" class="t s4_145">systemic therapy, morbidity is also a moving target. Combined modality </span>
<span id="t2d_145" class="t s4_145">therapy is generally recommended for the approximately 60% of patients </span>
<span id="t2e_145" class="t s4_145">with locally or regionally advanced disease at diagnosis. </span>
<span id="t2f_145" class="t s4_145">Participation in clinical trials is a preferred or recommended treatment </span>
<span id="t2g_145" class="t s4_145">option in many situations. In formulating these NCCN Guidelines, panel </span>
<span id="t2h_145" class="t s4_145">members have tried to make them evidence-based while providing a </span>
<span id="t2i_145" class="t s4_145">statement of consensus as to the acceptable range of treatment options. </span>
<span id="t2j_145" class="t s4_145">In numerous population-based studies, patients treated at high-volume </span>
<span id="t2k_145" class="t s9_145">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
